IP Library Granted Patent US 11,617,793
Granted Patent B2
US 11,617,793 · App. 17/871,825 · Granted Apr 4, 2023

Anhydrous sodium thiosulfate and formulations thereof

Inventors: Thomas Claiborne Lovelace (Apex, NC); Joseph Alexander Moore, III (Wake Forest, NC); Christopher Mckinnon Lee (Holy Springs, NC); Daniel Logan Kirschner (Raleigh, NC)
Assignee: Fennec Pharmaceuticals, Inc.
A61K47/20A61K9/0019A61K9/08A61K33/04A61K33/243A61K47/02A61K47/18A61K47/183
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,617,793
App. No.
17/871,825
Granted
Apr 4, 2023
Kind
B2
Abstract

Described herein is anhydrous sodium thiosulfate, methods for synthesizing anhydrous sodium thiosulfate, pharmaceutical compositions thereof, and methods of treating ototoxicity. Anhydrous sodium thiosulfate is synthesized from sodium sulfite, sulfur, and cetylpyridinium chloride. The anhydrous sodium thiosulfate is formulated into a pharmaceutical composition comprising a buffer and solvent. These compositions are useful for eliminating or reducing ototoxicity in pediatric patients receiving platinum-based chemotherapeutics.

Claims (8)

1. A pharmaceutical composition comprising sodium thiosulfate at a concentration of about 0.5 M and further comprising about 0.004 M boric acid wherein the pharmaceutical composition has a pH between about 6.5 and about 8.9.

2. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition has a total volume of about 100 mL.

3. The pharmaceutical composition of claim 2 , wherein the pharmaceutical composition further comprises hydrochloric acid.

4. The pharmaceutical composition of claim 2 , wherein the pharmaceutical composition further comprises sodium hydroxide.

5. The pharmaceutical composition of claim 2 , wherein the pharmaceutical composition has a pH between about 8.6 and about 8.8.

6. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition further comprises hydrochloric acid.

7. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition further comprises sodium hydroxide.

8. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition has a pH between about 8.6 and about 8.8.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 16, 2024
From: SMITH, ALEXANDER
To: ADS PHARMA CONSULTING, LLC
Reel/Frame 066137/0344 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 16, 2024
From: ADS PHARMA CONSULTING, LLC
To: FENNEC PHARMACEUTICALS, INC.
Reel/Frame 066137/0370 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 28, 2022
From: LOVELACE, THOMAS CLAIBORNE; MOORE, JOSEPH ALEXANDER, III; LEE, CHRISTOPHER MCKINNON; KIRSCHNER, DANIEL LOGAN
To: AVISTA PHARMA SOLUTIONS, INC.
Reel/Frame 061241/0568 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 28, 2022
From: AVISTA PHARMA SOLUTIONS, INC.
To: FENNEC PHARMACEUTICALS, INC.
Reel/Frame 061241/0582 →
Continuity (6)
Continuation 17584257 · Jan 25, 2022
Continuation 17005997 · Aug 28, 2020
Continuation 16458261 · Jul 1, 2019
Provisional Application 62693503 · Jul 3, 2018
Provisional Application 62693502 · Jul 3, 2018
Related Publication 20220378915A1 · Dec 1, 2022
Cited By (1)
US 12,653,838